128 related articles for article (PubMed ID: 8860430)
1. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats.
Kagatani S; Shinoda T; Fukui M; Ohmura T; Hasumi S; Sonobe T
Pharm Res; 1996 May; 13(5):739-43. PubMed ID: 8860430
[TBL] [Abstract][Full Text] [Related]
2. Nasal absorption kinetic behavior of azetirelin and its enhancement by acylcarnitines in rats.
Kagatani S; Inaba N; Fukui M; Sonobe T
Pharm Res; 1998 Jan; 15(1):77-81. PubMed ID: 9487550
[TBL] [Abstract][Full Text] [Related]
3. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-beta-cyclodextrins.
Sinswat P; Tengamnuay P
Int J Pharm; 2003 May; 257(1-2):15-22. PubMed ID: 12711157
[TBL] [Abstract][Full Text] [Related]
4. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats.
Ahsan F; Arnold J; Meezan E; Pillion DJ
Pharm Res; 2001 Dec; 18(12):1742-6. PubMed ID: 11785695
[TBL] [Abstract][Full Text] [Related]
5. Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes.
Cho W; Kim MS; Jung MS; Park J; Cha KH; Kim JS; Park HJ; Alhalaweh A; Velaga SP; Hwang SJ
Int J Pharm; 2015 Jan; 478(1):288-296. PubMed ID: 25445994
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride.
du Plessis LH; Lubbe J; Strauss T; Kotzé AF
Int J Pharm; 2010 Jan; 385(1-2):181-6. PubMed ID: 19854253
[TBL] [Abstract][Full Text] [Related]
7. Methylated beta-cyclodextrins are able to improve the nasal absorption of salmon calcitonin.
Schipper NG; Verhoef JC; Romeijn SG; Merkus FW
Calcif Tissue Int; 1995 Apr; 56(4):280-2. PubMed ID: 7767838
[TBL] [Abstract][Full Text] [Related]
8. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats.
Lee KC; Park MO; Na DH; Youn YS; Lee SD; Yoo SD; Lee HS; DeLuca PP
Calcif Tissue Int; 2003 Dec; 73(6):545-9. PubMed ID: 14508623
[TBL] [Abstract][Full Text] [Related]
9. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep.
Hinchcliffe M; Jabbal-Gill I; Smith A
J Pharm Pharmacol; 2005 Jun; 57(6):681-7. PubMed ID: 15969922
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT).
Sinko PJ; Lee YH; Makhey V; Leesman GD; Sutyak JP; Yu H; Perry B; Smith CL; Hu P; Wagner EJ; Falzone LM; McWhorter LT; Gilligan JP; Stern W
Pharm Res; 1999 Apr; 16(4):527-33. PubMed ID: 10227707
[TBL] [Abstract][Full Text] [Related]
11. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061
[TBL] [Abstract][Full Text] [Related]
12. Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent.
Matsuyama T; Morita T; Horikiri Y; Yamahara H; Yoshino H
J Control Release; 2006 Oct; 115(2):183-8. PubMed ID: 16989920
[TBL] [Abstract][Full Text] [Related]
13. [Study on pulmonary delivery system of salmon calcitonin in rats].
Wang Z; Zhang Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2003 Jun; 35(3):329-32. PubMed ID: 12914259
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats.
Wu L; Zhang G; Lu Q; Sun Q; Wang M; Li N; Gao Z; Sun Y; Li T; Han D; Yu X; Wang L; Sun W; Zhao D; Wu Y; Lu Y; Chen X
Drug Dev Ind Pharm; 2010 Mar; 36(3):362-70. PubMed ID: 19719396
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo characterisation of PEG-lipid-based micellar complexes of salmon calcitonin for pulmonary delivery.
Baginski L; Gobbo OL; Tewes F; Salomon JJ; Healy AM; Bakowsky U; Ehrhardt C
Pharm Res; 2012 Jun; 29(6):1425-34. PubMed ID: 22322897
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary absorption enhancement of salmon calcitonin.
Mahesh Kumar T; Misra A
J Drug Target; 2004 Apr; 12(3):135-44. PubMed ID: 15203892
[TBL] [Abstract][Full Text] [Related]
17. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Sep; 8():5. PubMed ID: 18782439
[TBL] [Abstract][Full Text] [Related]
18. The influence of the enhancer dimyristoylphosphatidylglycerol and formulation factors on the nasal absorption of salmon calcitonin.
Dua R; Duncan M; Zia H; Needham TE
Drug Deliv; 1998; 5(2):127-34. PubMed ID: 19570004
[TBL] [Abstract][Full Text] [Related]
19. Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery.
Chen M; Li XR; Zhou YX; Yang KW; Chen XW; Deng Q; Liu Y; Ren LJ
Peptides; 2009 Jul; 30(7):1288-95. PubMed ID: 19540427
[TBL] [Abstract][Full Text] [Related]
20. Synergistic absorption enhancement of salmon calcitonin and reversible mucosal injury by applying a mucolytic agent and a non-ionic surfactant.
Takatsuka S; Morita T; Koguchi A; Horikiri Y; Yamahara H; Yoshino H
Int J Pharm; 2006 Jun; 316(1-2):124-30. PubMed ID: 16600541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
